Deutsche Bank AG Makes New $3.56 Million Investment in Aurinia Pharmaceuticals Inc $AUPH

Key Points

• Deutsche Bank AG acquired 210,005 shares of Aurinia Pharmaceuticals in the second quarter, worth approximately $3.56 million and representing about 0.16% of the company.
• Institutional and hedge-fund interest increased notably, with several investors—including Arrowstreet Capital, Marshall Wace, and Two Sigma—substantially expanding their positions. Institutions collectively owned 36.83% of Aurinia’s stock.
• Aurinia exceeded quarterly EPS expectations, reporting $0.28 versus the $0.24 consensus estimate, though revenue of $58.57 million fell short of the $80.45 million forecast. Analysts maintain a “Moderate Buy” consensus with an average price target of $17.67.

Deutsche Bank AG purchased a new stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 210,005 shares of the biotechnology company's stock, valued at approximately $3,564,000. Deutsche Bank AG owned approximately 0.16% of Aurinia Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in AUPH. Arrowstreet Capital Limited Partnership boosted its holdings in Aurinia Pharmaceuticals by 213.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 3,374,021 shares of the biotechnology company's stock worth $37,283,000 after acquiring an additional 2,297,903 shares in the last quarter. Marshall Wace LLP raised its position in shares of Aurinia Pharmaceuticals by 1,272.5% during the third quarter. Marshall Wace LLP now owns 1,483,132 shares of the biotechnology company's stock worth $16,389,000 after purchasing an additional 1,375,072 shares during the period. Kotler Kevin bought a new position in shares of Aurinia Pharmaceuticals in the 4th quarter worth $19,536,000. Two Sigma Investments LP lifted its holdings in shares of Aurinia Pharmaceuticals by 728.6% in the 3rd quarter. Two Sigma Investments LP now owns 1,341,067 shares of the biotechnology company's stock worth $14,819,000 after purchasing an additional 1,179,219 shares in the last quarter. Finally, Man Group plc grew its position in Aurinia Pharmaceuticals by 368.9% in the 4th quarter. Man Group plc now owns 852,671 shares of the biotechnology company's stock valued at $13,600,000 after purchasing an additional 670,812 shares during the period. Institutional investors and hedge funds own 36.83% of the company's stock.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ AUPH opened at $16.54 on Thursday. The company has a market capitalization of $2.20 billion, a PE ratio of 7.22 and a beta of 1.42. The company has a quick ratio of 4.97, a current ratio of 5.42 and a debt-to-equity ratio of 0.07. The stock's 50 day moving average price is $15.98 and its 200-day moving average price is $15.47. Aurinia Pharmaceuticals Inc has a twelve month low of $10.34 and a twelve month high of $19.25.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.28 EPS for the quarter, beating analysts' consensus estimates of $0.24 by $0.04. Aurinia Pharmaceuticals had a return on equity of 26.11% and a net margin of 100.84%.The company had revenue of $58.57 million during the quarter, compared to the consensus estimate of $80.45 million. On average, equities analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.79 EPS for the current year.

Analyst Upgrades and Downgrades

AUPH has been the topic of a number of recent research reports. Bloom Burton raised shares of Aurinia Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 20th. Royal Bank Of Canada boosted their target price on shares of Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the stock a "sector perform" rating in a research report on Friday, August 7th. Zacks Research lowered shares of Aurinia Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 21st. Wall Street Zen cut shares of Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. Finally, Weiss Ratings reiterated a "hold (c+)" rating on shares of Aurinia Pharmaceuticals in a research note on Wednesday, August 12th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Aurinia Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $17.67.

Insider Buying and Selling at Aurinia Pharmaceuticals

In related news, CEO Kevin Tang purchased 343,620 shares of Aurinia Pharmaceuticals stock in a transaction that occurred on Monday, June 1st. The stock was bought at an average price of $15.28 per share, for a total transaction of $5,250,513.60. Following the completion of the transaction, the chief executive officer owned 12,838,101 shares in the company, valued at $196,166,183.28. This represents a 2.75% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders have bought 814,606 shares of company stock valued at $12,455,129. 10.40% of the stock is currently owned by insiders.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company's proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company's lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.

Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source